AMLX · Amylyx Pharmaceuticals, Inc.

The thesis

Amylyx Pharmaceuticals' case rests on one drug, avexitide, reaching a New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) by year-end 2026. The shares have recovered part of the October slide but remain below the $35.50 August offering price, so the market has not yet endorsed the timetable. The third-quarter report, estimated for about 5 November 2026, and an announced submission by 31 December 2026 settle it.

The clinical result is unchanged. On 18 August 2026 Amylyx reported that avexitide cut the combined rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in the Phase 3 LUCIDITY trial in post-bariatric hypoglycemia (PBH). On 6 October 2026 the company said it will present the topline data in a late-breaking oral session at ObesityWeek, 14-17 November 2026, and kept its plan for an NDA by end of 2026 and a potential 2027 launch.

The narrative is maturing: the readout is ten weeks old, and the only new items since the 14 October 2026 close are a Citigroup target increase and a rebound. Citigroup kept its Buy rating and raised its price target to $39 on 15 October 2026 (company news). The adjusted close was $28.30 on 27 October 2026, up from $27.03 on 14 October 2026, and 28.6% below the $39.66 52-week high. The 14-day Relative Strength Index (RSI) has moved from 26.4 to 54.2 over that span, and the shares are up 36.4% over three months.

Bullish and bearish views on Amylyx Pharmaceuticals, Inc.

The bull case on Amylyx Pharmaceuticals, Inc. (AMLX), in brief: The pivotal trial met every endpoint. The bear case: Buyers in that offering hold a loss, which can weigh on any rebound toward $35.50.

Bull case

• The pivotal trial met every endpoint. LUCIDITY randomized 78 adults and met its primary and all secondary endpoints, per the 18 August 2026 release. Avexitide holds FDA Breakthrough Therapy Designation in PBH and congenital hyperinsulinism.
• Launch funding is in place. The 19 August 2026 underwriting agreement specified about $471.7 million in expected net proceeds, with launch preparation and manufacturing capacity among the stated uses (Form 8-K).
• Commercial supply is being contracted. Amylyx disclosed an agreement with Bachem Americas and a term sheet with PolyPeptide Group to supply avexitide from 2028, including a $30 million upfront capacity reservation fee, as reported by Simply Wall St on 19 September 2026.
• Full data goes public in November. The ObesityWeek oral presentation on 14-17 November 2026 gives clinicians the complete LUCIDITY dataset, per the company's 6 October 2026 announcement.
• Analyst targets sit above the price. The consensus average target is $42.36 across 12 analysts, with a range of $20 to $57 (MarketScreener, 2 October 2026). Citigroup raised its target to $39 on 15 October 2026; Stifel's $45 and Mizuho's $42 followed the August offering.

Bear case

• Buyers in that offering hold a loss, which can weigh on any rebound toward $35.50.
• One asset carries the valuation. Amylyx has had no product revenue since RELYVRIO/ALBRIOZA was withdrawn in April 2024, and AMX-0035, AMX-114 and AMX-318 have no near-term registrational readout.
• The trial was small and short. LUCIDITY enrolled 78 patients over a 16-week double-blind period, which leaves the FDA room to ask about durability and longer-term safety.
• The filing date is a company target. The year-end submission is guidance, not a scheduled event. Searches of company releases found no announced submission as of 28 October 2026.
• The rebound has little new company news behind it. No company disclosure since 6 October 2026 explains the move from $27.03 to $28.30, so it may fade if the November events add nothing.

Price setup

The adjusted close of $28.30 on 27 October 2026 sits 28.6% below the 52-week high of $39.66 and well below the $35.50 offering price. The 14-day RSI of 54.2 is neutral; the 26.4 reading on 14 October 2026 has cleared. The $25 weekly-close level in the previous note remains the nearest downside marker, and $35.50 is the first overhead reference where offering buyers break even.

Crowding evidence is limited. The earnings report is about eight days away, and the shares rose 36.4% over three months, a period that includes the August readout and offering. No Form 4 insider sale or new share issuance has been found since the August offering.

Catalysts, next 30 days

• 14 November 2026: ObesityWeek late-breaking oral presentation. The meeting runs 14-17 November in Washington, D.C. Durability, safety and dropout detail come under review.
• 31 December 2026: Company-guided NDA deadline. It falls outside the 30-day window, but the case turns on it. An announced submission completes the regulatory half; a year ending without one breaks it.

Elapsed catalysts

• ~5 November 2026 (est.): Third-quarter 2026 financial results. First cash balance after the August offering, and the first chance for Amylyx to reaffirm or move the year-end NDA timetable. The date is unconfirmed. (passed 1d ago)

What would change the view

The case breaks if Amylyx moves NDA guidance into 2027, or if 31 December 2026 passes without an announced avexitide submission. It also breaks if the FDA asks for additional controlled efficacy or longer-term safety data before filing. Full ObesityWeek data that diverges from the 55% topline reduction, through weaker durability, tolerability or higher dropouts, would weaken it.

On price, a weekly close below $25 would extend the slide under the $35.50 offering price and end the thesis. A reaffirmed year-end filing at the third-quarter report, with a clean full-data presentation, would strengthen it.

What it trades with

Avexitide is a GLP-1 receptor antagonist, the opposite mechanism to semaglutide and tirzepatide, so GLP-1 agonist headlines are an unreliable read-across. The shares trade on company-specific events: the earnings report, the ObesityWeek presentation and the filing. Small-cap biotech sentiment can move the shares around those dates, but the stock has no commercial revenue to link it to sector earnings.